Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program
Authors
Keywords
Edema, Albumins, Venous thromboembolism, Thrombosis, Non-small cell lung cancer, Phase II clinical investigation, Adverse events, Cancer treatment
Journal
PLoS One
Volume 10, Issue 10, Pages e0139679
Publisher
Public Library of Science (PLoS)
Online
2015-10-08
DOI
10.1371/journal.pone.0139679
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)
- (2014) H.A. Wakelee et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC)
- (2014) F.R. Hirsch et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- ET-12 * PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
- (2014) T. Cloughesy et al. NEURO-ONCOLOGY
- Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
- (2014) Elizabeth Smyth et al. OncoTargets and Therapy
- Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration-Effect Data to Support Clinical Development
- (2013) H. Xiang et al. CLINICAL CANCER RESEARCH
- Cardiohepatic Interactions in Heart Failure
- (2013) Marc D. Samsky et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab
- (2013) E. Mai et al. MOLECULAR CANCER THERAPEUTICS
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
- (2012) C. J. Ryan et al. CLINICAL CANCER RESEARCH
- Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody
- (2012) J M Lee et al. ONCOGENE
- Non-Agonistic Bivalent Antibodies That Promote c-MET Degradation and Inhibit Tumor Growth and Others Specific for Tumor Related c-MET
- (2012) Sameer A. Greenall et al. PLoS One
- Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and β-catenin/Wnt pathways
- (2010) Sara Previdi et al. EUROPEAN JOURNAL OF CANCER
- Hepatocyte growth factor activator (HGFA): a serine protease that links tissue injury to activation of hepatocyte growth factor
- (2010) Keiji Miyazawa FEBS Journal
- Lymphedema: A primer on the identification and management of a chronic condition in oncologic treatment
- (2009) B. D. Lawenda et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ascites: Diagnosis and Management
- (2009) Wei Hou et al. MEDICAL CLINICS OF NORTH AMERICA
- Paxillin Is Involved in the Differential Regulation of Endothelial Barrier by HGF and VEGF
- (2008) Anna A. Birukova et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search